Xerava

RSS

eravacycline

Authorised
This medicine is authorised for use in the European Union.

Overview

Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults. ‘Complicated’ means that the infection is difficult to treat because it has spread to the abdominal space.

Xerava contains the active substance eravacycline.

This EPAR was last updated on 10/07/2019

Authorisation details

Product details
Name
Xerava
Agency product number
EMEA/H/C/004237
Active substance
eravacycline
International non-proprietary name (INN) or common name
eravacycline
Therapeutic area (MeSH)
  • Infection
  • Bacterial Infections
Anatomical therapeutic chemical (ATC) code
J01AA
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Tetraphase Pharmaceuticals Ireland Limited
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
20/09/2018
Contact address
10 Earlsfort Terrace
Dublin 2 D02 T380
Ireland

Product information

25/04/2019 Xerava - EMEA/H/C/004237 - IB/0004

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating